Kiora Pharmaceuticals, Inc. (KPRX): History, Ownership, Mission, How It Works & Makes Money

Are you curious about Kiora Pharmaceuticals (KPRX) and its mission to combat retinal diseases? This clinical-stage biopharmaceutical company is dedicated to developing innovative treatments, particularly for orphan retinal diseases, with the goal of preserving, slowing, or even restoring vision loss. Keep reading to explore Kiora Pharmaceuticals' history, ownership, how it operates, and how it aims to generate revenue in the competitive biotech landscape, especially with its strong financial position with $29.0 million in cash and equivalents reported in Q3 2024.

Kiora Pharmaceuticals, Inc. (KPRX) History

Kiora Pharmaceuticals, Inc. Founding Timeline

Year established

The company was re-named as Kiora Pharmaceuticals, Inc. in 2019.

Original location

Kiora Pharmaceuticals, Inc. is headquartered in Irvine, California.

Founding team members

Although specific founding team members are not explicitly detailed, the leadership and key figures driving the company's strategic direction and operations include:

• Brian M. Strem, Ph.D.: President and Chief Executive Officer
• Mark облицовканда, J.D.: Chief Financial Officer

Initial capital/funding

Information regarding the initial capital or funding at the time of original establishment/founding is not available in the provided search results.

Kiora Pharmaceuticals, Inc. Evolution Milestones

Kiora Pharmaceuticals, Inc. Transformative Moments

• Strategic Re-branding (2019): The renaming to Kiora Pharmaceuticals, Inc. marked a pivotal moment, signaling a new strategic direction and focus for the company.
• Successful Private Placements: Securing significant funding through private placements, such as the $12 million placement in 2020, provided crucial capital for advancing clinical programs and strengthening the company's financial position.
• Positive Clinical Data: The announcement of positive topline data from the Phase 2 ABLE-1 study of KIO-101 in 2021 was a transformative moment, validating the potential of the company's pipeline and driving further development efforts.
• FDA Clearance of IND Application: The FDA clearance of the IND application for KIO-301 in retinitis pigmentosa in 2023 represented a major milestone, enabling the company to initiate clinical trials and progress the development of this promising therapy.

To gain more insights into the investors and motivations behind Kiora Pharmaceuticals, explore this in-depth analysis: Exploring Kiora Pharmaceuticals, Inc. (KPRX) Investor Profile: Who’s Buying and Why?

Kiora Pharmaceuticals, Inc. (KPRX) Ownership Structure

Understanding the ownership structure of Kiora Pharmaceuticals, Inc. provides insights into the company's control and governance. The ownership is distributed among various shareholders, including institutional investors, individual shareholders, and company insiders, each holding different percentages of the company's stock.

Kiora Pharmaceuticals, Inc. Current Status

Kiora Pharmaceuticals, Inc. is a publicly traded company, which means its shares are available for purchase by the general public on a stock exchange. The company is listed on the NASDAQ Capital Market under the ticker symbol KPRX.

Kiora Pharmaceuticals, Inc. Ownership Breakdown

The following table provides an overview of the ownership breakdown of Kiora Pharmaceuticals, Inc., detailing the different types of shareholders and their respective ownership percentages.

Kiora Pharmaceuticals, Inc. Leadership

The leadership team at Kiora Pharmaceuticals, Inc. is responsible for the strategic direction and operational management of the company. Key members of the leadership team include:

• Brian M. Strem, Ph.D.: President and Chief Executive Officer
• Scott M. Praill, CPA: Chief Financial Officer
• Mark Hoffman, Ph.D.: Chief Scientific Officer

These individuals bring a wealth of experience and expertise to Kiora Pharmaceuticals, Inc., guiding the company in its mission to develop and commercialize novel therapies for ophthalmic diseases. For insights into the company's goals, see: Mission Statement, Vision, & Core Values of Kiora Pharmaceuticals, Inc. (KPRX).

Kiora Pharmaceuticals, Inc. (KPRX) Mission and Values

Kiora Pharmaceuticals is dedicated to discovering, developing, and commercializing novel therapies for ophthalmic diseases, aiming to improve patients' vision and quality of life. The company's values are centered around innovation, integrity, and patient-centricity, guiding its strategic decisions and operational practices.

Kiora Pharmaceuticals' Core Purpose

Official mission statement

Kiora Pharmaceuticals' mission is to be a leader in bringing innovative solutions to patients with sight-threatening and debilitating ophthalmic diseases. This involves:

• Developing and delivering transformative therapies.
• Focusing on areas of high unmet need in ophthalmology.
• Maintaining the highest standards of scientific rigor and ethical conduct.

Vision statement

Kiora Pharmaceuticals envisions a future where vision loss due to ophthalmic diseases is significantly reduced, and patients have access to effective treatments that restore and preserve their sight. Key aspects of this vision include:

• Becoming a recognized leader in the field of ophthalmic therapeutics.
• Expanding the pipeline of innovative products to address a wide range of eye diseases.
• Collaborating with leading researchers, clinicians, and patient advocacy groups to advance the field of ophthalmology.

Company slogan/tagline

While Kiora Pharmaceuticals does not have a single, publicly promoted slogan, their activities and communications reflect a commitment to 'Innovation for Vision.' This theme is evident in their focus on novel therapies and dedication to improving patient outcomes.

To learn more about the company's investors and stakeholders, check out: Exploring Kiora Pharmaceuticals, Inc. (KPRX) Investor Profile: Who’s Buying and Why?

Kiora Pharmaceuticals, Inc. (KPRX) How It Works

Kiora Pharmaceuticals, Inc. (KPRX) focuses on the development and commercialization of products for the treatment of ophthalmic diseases, aiming to address significant unmet needs in eye care. The company operates by identifying, developing, and seeking regulatory approval for innovative therapies designed to improve patient outcomes.

Kiora Pharmaceuticals, Inc.'s Product/Service Portfolio

Kiora Pharmaceuticals, Inc.'s Operational Framework

Kiora Pharmaceuticals, Inc. operates through a streamlined process that integrates research, development, and strategic partnerships to advance its pipeline of ophthalmic therapies.

• Research and Development: Kiora focuses on innovative approaches to address unmet needs in eye care. The company's primary focus is on KIO-301, a molecule designed to restore vision in patients with inherited or retinal degeneration.
• Clinical Trials: Kiora conducts clinical trials to evaluate the safety and efficacy of its product candidates. These trials are essential for gathering data required for regulatory submissions and approvals.
• Regulatory Approval: Kiora works closely with regulatory agencies, such as the FDA in the United States, to secure approval for its products. This involves submitting comprehensive data packages demonstrating safety and efficacy.
• Strategic Partnerships: Kiora collaborates with other pharmaceutical companies and research institutions to leverage expertise and resources. These partnerships can help accelerate the development and commercialization of its products.
• Manufacturing and Supply Chain: Kiora establishes relationships with contract manufacturing organizations (CMOs) to manufacture its products. Ensuring a reliable supply chain is critical for meeting the demands of the market once products are approved.

For more insights into the company's journey and investor profile, check out: Exploring Kiora Pharmaceuticals, Inc. (KPRX) Investor Profile: Who’s Buying and Why?

Kiora Pharmaceuticals, Inc.'s Strategic Advantages

Kiora Pharmaceuticals, Inc. possesses several strategic advantages that position it for success in the competitive ophthalmic market:

• Innovative Technology: KIO-301 represents a novel approach to restoring vision by converting retinal ganglion cells into light-sensing cells, potentially offering a solution for patients with limited or no light perception.
• Targeted Therapies: By focusing on specific ophthalmic diseases with unmet needs, Kiora can tailor its development efforts and commercialization strategies for maximum impact.
• Experienced Management Team: A skilled leadership team with expertise in drug development, regulatory affairs, and commercialization can guide the company through the complex process of bringing new therapies to market.
• Intellectual Property: Strong patent protection for its product candidates provides Kiora with a competitive advantage and exclusivity in the market.
• Strategic Collaborations: Partnerships with other companies and institutions can provide access to additional resources, expertise, and funding, accelerating the development and commercialization of its products.

Kiora Pharmaceuticals, Inc. (KPRX) How It Makes Money

Kiora Pharmaceuticals, Inc. operates as a biopharmaceutical company, primarily focused on the discovery, development, and commercialization of products for the treatment of ophthalmic diseases. Kiora generates revenue through strategic partnerships, licensing agreements, and potentially, direct sales of its developed products upon regulatory approval.

Kiora Pharmaceuticals, Inc. Revenue Breakdown

As Kiora Pharmaceuticals is still in the clinical development stage, detailed revenue breakdowns are not yet available. The company's financial information primarily reflects investments, expenses related to research and development, and funding through stock offerings and other financial activities. Once Kiora successfully commercializes its products, revenue streams will likely include product sales, licensing agreements, and royalties.

Kiora Pharmaceuticals, Inc. Business Economics

Kiora's business economics are centered around the high-risk, high-reward model typical of pharmaceutical companies. Key aspects include:

• R&D Investments: A significant portion of Kiora's expenditure is allocated to research and development. Successfully navigating clinical trials is crucial for the economic viability of their products.
• Intellectual Property: Patents and proprietary formulations are vital assets, providing market exclusivity and protecting investments.
• Regulatory Approval: Securing regulatory approval from bodies such as the FDA is a critical milestone that allows Kiora to commercialize its products.
• Partnerships: Strategic alliances for development, manufacturing, and distribution can reduce financial risks and accelerate market entry.

Kiora Pharmaceuticals, Inc. Financial Performance

As of the fiscal year 2024, Kiora's financial performance reflects its status as a development-stage company. Key points include:

• Cash Position: Monitoring cash reserves is essential to fund ongoing research and development activities.
• Operating Expenses: These include R&D costs, clinical trial expenses, and administrative overhead. Efficient management of these expenses is vital.
• Net Loss: As a company still in the development phase, Kiora is likely to report a net loss, reflecting its investment in future growth.
• Financing Activities: Kiora has been actively involved in financing activities to support its operations, including raising capital through stock offerings. For instance, in March 2024, Kiora announced a public offering, expecting gross proceeds of $6.0 million.

To gain more insight into Kiora's values, check out Mission Statement, Vision, & Core Values of Kiora Pharmaceuticals, Inc. (KPRX).

Kiora Pharmaceuticals, Inc. (KPRX) Market Position & Future Outlook

Kiora Pharmaceuticals is navigating a challenging market landscape as it focuses on developing and commercializing therapies for ophthalmic diseases. The company's future success hinges on the clinical trial outcomes of its lead product candidates and its ability to secure additional funding.

Competitive Landscape

The competitive landscape for Kiora Pharmaceuticals includes both established pharmaceutical companies with broad portfolios and smaller biotech firms focused on specific ophthalmic indications.

*Market share data for Kiora Pharmaceuticals is not currently available, reflecting its developmental stage and lack of commercially available products as of April 2025. The percentages for Regeneron and Novartis are estimates based on the overall anti-VEGF market.

Opportunities & Challenges

Kiora Pharmaceuticals faces a mix of opportunities and challenges as it strives to bring its innovative therapies to market.

Industry Position

• Kiora Pharmaceuticals is an emerging player in the ophthalmic therapeutics market, focused on developing innovative therapies for vision restoration.
• The company's industry position is characterized by its early-stage development programs and its focus on addressing unmet needs in inherited retinal diseases.
• Kiora's success will depend on its ability to successfully navigate the clinical trial process, secure regulatory approvals, and commercialize its product candidates.

For more insights into Kiora Pharmaceuticals' financial standing, consider exploring this analysis: Breaking Down Kiora Pharmaceuticals, Inc. (KPRX) Financial Health: Key Insights for Investors